Skip to main content

Delphic Acquires Dx Business of iQur

NEW YORK (GenomeWeb News) – Pharmacogenomics test developer and specialty lab company Delphic has acquired the diagnostics business of iQur.

London-based iQur specializes in liver diagnostics and therapies. Delphic, which also is based in London, said in a statement that the acquisition would enable it to "leverage its capabilities and infrastructure to offer improved services in infectious diseases to the clinical and clinical trials markets, and to access the growing market for blood-borne virus screening."

iQur will continue to supply its ELF liver fibrosis test, which measures three serum markers that have been shown to correlate with the level of liver fibrosis, in partnership with Siemens.

iQur said that it would now focus on its vaccines program targeted as hepatitis, other infections, and cancer.

Financial terms of the acquisition were not disclosed.

Filed under

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.